Another study presented schisandrin B as a neuroprotector for rats in a model of amyloid beta peptide (Aβ)-infused Alzheimer’s disease (AD), and revealed the potential role of schisandrin B for the cognitive improvement via the inhibition of the receptor for advanced glycation end products (RAGE)/NF-κB/MAPK axis [132]. Here, AGER is linked to early-onset autosomal dominant Alzheimer disease.